Navigation Links
Mentice AB Announces the Appointment of Lars Lonn as Clinical Director for Mentice
Date:3/28/2008

GOTHENBURG, Sweden, March 28 /PRNewswire/ -- Mentice AB, a leading supplier of virtual reality based training applications within the field of medicine has recently appointed Lars Lonn as Clinical Director for Mentice.

Professor Lonn, an Interventional Radiologist, is also a leading European professor within the field of Endovascular Surgery and a faculty member of Rigshospital Health Sciences in Copenhagen, Denmark.

Professor Lonn recently completed a study with Max Berry, MD, Mikael Hellstrom, MD, Jan Gothlin, MD, and Richard Reznick, MD, MEd, FRCSC, which was featured in the Journal of Vascular Interventional Radiology entitled, "Endovascular Training with Animals versus Virtual Reality Systems: An Economic Analysis."

Goran Malmberg, CEO and President of Mentice said, "This is a monumental step forward for us. Professor Lonn will have a vital role with Mentice verifying the direction of our product development, while increasing the awareness and need for training solutions in healthcare. In the long run, we feel that Clinical Directors will play a vital role in driving medical training through the use of medical simulation."

About Mentice:

Mentice is a leader in medical simulation with approximately 600 installations worldwide, 100 validation studies and more than 30 issued and pending patents. Mentice's Family of Procedicus (TM) simulators focus on the area of minimally invasive surgery within the fields of endovascular intervention, core skills training, laparoscopy and arthroscopy training.

Website info: http://www.mentice.com

For more information contact: Goran Malmberg at +46 31 33 99 401 (Gothenburg office) or email, goran.malmberg@mentice.com.

Release #32808


'/>"/>
SOURCE Mentice Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Mentice AB Announces Leadership Changes Within Its Worldwide Operations
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
4. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
5. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
6. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
7. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... DANVILLE, Pa. , Aug. 19, 2014 ... C has been nominated for a Centers for Disease ... to addressing a major public health concern. ... Health System, is one of a team of researchers ... (CDC) Charles C. Shepard Science Award for Data Methods ...
(Date:8/19/2014)... 19, 2014 Robin Williams’ passing is ... take on an individual. Symptoms range from slowness ... problems swallowing and severe depression. Parkinson’s disease progressively ... of dopamine producing neurons of the brain. As ... that slowly and progressively gets worse, they look for ...
(Date:8/19/2014)... CSSi, the leader in patient recruitment solutions ... of the company,s Medical and Clinical Advisory Board ("MCAB") ... William E. Gannon, Jr. to the MCAB. ... The MCAB, with Dr. Gannon,s leadership, will help ... set strategic goals for the advancement and development of ...
(Date:8/19/2014)... 2014 /PRNewswire/ - iCo Therapeutics Inc. ("iCo" or "the ... of its Oral Amphotericin B (Oral Amp B) ... conducted by ImmuneCarta®, the immune monitoring business unit ... of Oral Amp B in reactivating latent HIV ... intensive treatment with antiretroviral therapy. ...
Breaking Biology Technology:Geisinger investigator nominated for federal award 2Geisinger investigator nominated for federal award 3As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 2As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 3CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 2CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 3iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 3
... financial guidance through second quarter of 2009 - ... - Conference ... BRANFORD, Conn., Nov. 3 CuraGen Corporation,(Nasdaq: CRGN ), today ... the three month period ended September 30, 2008, CuraGen,utilized $3.6 million ...
... and terms of his settlement with the SEC. Case No. 2:08-cv-2252-GEB-DAD. ... ... Rancho Cordova, California Corporation, was formed in 2005 to develop and ... cancer, particularly diseases related to chromosomal telomere shortening. The Company worked ...
... Memory,Pharmaceuticals Corp. (Nasdaq: MEMY ) today announced ... Company,s request for an,extension until December 3, 2008 ... capitalization requirement of $35 million or the alternative,requirement ... to remain,listed. There can be no assurance that ...
Cached Biology Technology:CuraGen Reports Third Quarter 2008 Financial Results 2CuraGen Reports Third Quarter 2008 Financial Results 3CuraGen Reports Third Quarter 2008 Financial Results 4CuraGen Reports Third Quarter 2008 Financial Results 5CuraGen Reports Third Quarter 2008 Financial Results 6Former Telomolecular CEO Clarifies SEC Settlement 2Former Telomolecular CEO Clarifies SEC Settlement 3Memory Pharmaceuticals Granted Extension to Comply with NASDAQ Listing Requirements 2
(Date:8/20/2014)... August 19, 2014 -- Bay Area Lyme Foundation, which ... simple to cure, applauds new research published in an ... Ticks and Tick-borne Diseases . The findings show ... are active throughout the year, making the threat of ... at California Department of Public Health (CDPH) Vector-borne Disease ...
(Date:8/20/2014)... acral melanomas the rare type of skin cancer that ... from other more common types of skin cancer, according to ... Pigment Cell & Melanoma Research . , Acral melanoma most ... feet, nail-beds and other hairless parts of the skin. Unlike ... UV damage from the sun. , The team, from the ...
(Date:8/20/2014)... seawater signals a relaxing trip to the shore. But ... comes with an environmental hitch. When certain sunblock ingredients ... become toxic to some of the ocean,s tiniest inhabitants, ... animals. Their study appears in the ACS journal ... David Snchez-Quiles point out that other than staying indoors, ...
Breaking Biology News(10 mins):Lyme disease risk is year-round in Northwest California, according to new study 2Lyme disease risk is year-round in Northwest California, according to new study 3Scientists learn more about rare skin cancer that killed Bob Marley 2
... in Japan may have developed a way to accurately predict ... the standard of care for chronic myeloid leukemia (CML). ... a journal of the American Association for Cancer Research. ... treatment of leukemia when it was approved in 2001. Yet ...
... July 28 BIO-key International, Inc. (OTC Bulletin Board: ... financial results for the second quarter and six month period ... the data presented in this release relative to the same ... fingerprint-based Biometrics Division. The company completed the sale of its ...
... required to smoke "electronic cigarettes" marketed as ... with possible adverse effects on human health, researchers ... The researchers used a smoking machine to compare ... five e-cigarette brands. They examined the vacuum required ...
Cached Biology News:New lab test could identify imatinib resistance 2BIO-key® Reports Strong 2010 Second Quarter and Six Month Financial Results 2BIO-key® Reports Strong 2010 Second Quarter and Six Month Financial Results 3BIO-key® Reports Strong 2010 Second Quarter and Six Month Financial Results 4BIO-key® Reports Strong 2010 Second Quarter and Six Month Financial Results 5BIO-key® Reports Strong 2010 Second Quarter and Six Month Financial Results 6BIO-key® Reports Strong 2010 Second Quarter and Six Month Financial Results 7Electronic cigarettes require more suction than conventional brands 2Electronic cigarettes require more suction than conventional brands 3Electronic cigarettes require more suction than conventional brands 4